OncoC4 Bags $200 Million in CTLA-4 Antibody Pact with BioNTech

BioNTech and OncoC4 are partnering up to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392, as a monotherapy or combination therapy for various cancers.